Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

3 1 1

What is this study about?

The trial involves people who have long‑standing rhinitis or rhinoconjunctivitis, conditions that cause a runny or itchy nose and eyes, and who may also have mild‑to‑moderate asthma that is well controlled. These symptoms are triggered by allergens that cause IgE mediated allergies. To evaluate the allergy status, a series of solutions containing specific pollen extracts are used: parietaria judaica pollen extract (code SPT‑RX‑PAR), phleum pratense pollen extract (SPT‑RX‑PHL), betula pendula pollen extract (SPT‑RX‑BET), dermatophagoides pteronyssinus extract (SPT‑RX‑DPT), and olea europaea pollen extract (SPT‑RX‑OLE). Each solution is applied to the skin in a small amount for a diagnostic test.

The purpose of the study is to assess how well these extracts identify allergic versus non‑allergic individuals by measuring the test’s sensitivity and specificity. Participants will attend a clinic visit where a tiny amount of each solution is placed on the forearm and gently pricked into the skin using a skin prick test method; a control drop without allergen is also used. After a few minutes the size of any raised, red bump (called a wheal) is measured, and the results are compared with the person’s medical history to determine accuracy. The study follows participants for a short period after the test to complete the assessments.

1 initial visit for skin prick testing

upon joining the study, attend the designated clinic on the scheduled date for the diagnostic procedure.

the purpose of this visit is to perform a skin prick test using the study solutions.

2 skin prick test administration

a small amount (40 µl) of each allergen extract solution is placed on the skin and a sterile needle lightly punctures the surface.

the extracts used are parietaria judaica pollen, phleum pratense pollen, betula pendula pollen, dermatophagoides pteronyssinus, and olea europaea pollen.

the route is intraepidermal (into the outer skin layer).

3 observation and measurement

after the puncture, wait for approximately 15 minutes while the skin reaction develops.

the size of the raised bump (wheal) is measured in millimetres; a diameter of 3 mm or more is considered a positive result.

4 result recording and follow‑up

the measurements are recorded by the study staff and used to determine sensitivity and specificity of each extract.

no further medication is given; the patient may leave the clinic after the observation period.

Who Can Join the Study?

  • Signed a written informed consent form that is dated before any study-specific examinations are performed.
  • Are a male or female aged between 18 and 65 years at the time the consent form is signed.
  • Show a positive reaction (a raised bump of at least 3 mm) on a skin prick test using a positive control (histamine, a substance that normally causes a small skin reaction), and a negative reaction (bump less than 2 mm) on a skin prick test using a negative control (saline solution).
  • Can follow study instructions, keep a simple diary, and are expected to cooperate with the study staff.
  • Have ongoing nasal or eye allergy symptoms (rhinitis/rhinoconjunctivitis), with mild‑to‑moderate asthma that is well‑controlled or no asthma, caused by the study allergens for at least 2 years if the allergen is seasonal, or at least 1 year if the allergen is present year‑round.
  • Have a previous diagnosis of IgE‑mediated (type I) allergy to a study allergen, confirmed by:
    • a symptom score of 1 or higher on the Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS) during the period of highest exposure,
    • a positive skin prick test (bump at least 3 mm) with a standard allergen extract,
    • a blood test showing specific IgE level of class 3 or higher (value ≥ 3.50 kU/L).
  • If you have never had allergy symptoms (“true non‑allergic” patient), you must be either non‑atopic (no general allergy tendency) or only sensitized to allergens not being studied, proven by:
    • a negative skin prick test (bump less than 3 mm) for all study allergens, and
    • a blood test showing specific IgE level below class 1 (value < 0.35 kU/L) for those allergens.

Who Cannot Join the Study?

  • Using medicines that could change the results of the skin prick test (the test that checks for allergies).
  • Having skin problems such as easy skin bruising from pressure (dermographism), eczema (atopic dermatitis), hives (urticaria), a rare condition with many mast cells in the skin (cutaneous mastocytosis), or having a tattoo where the test would be applied.
  • Being unable to receive adrenaline (a medication used for severe allergic reactions) because of heart disease, very high blood pressure, an overactive thyroid, or glaucoma.
  • Any other medical reason that makes a skin prick test unsafe.
  • Being unlikely to follow the study rules and visits.
  • Having a close personal or financial relationship with the study sponsor or investigators, being legally unable to give consent, or being living in a government institution.
  • Having serious mental health problems or substance abuse that would prevent cooperation with the study.
  • Being enrolled in another clinical trial at the same time.
  • If you are considered “truly non‑allergic,” having a hidden sensitivity to any allergen that can react with the test allergens (cross‑reactivity).
  • For people with asthma: having severe, partly controlled, or uncontrolled asthma, a lung function test result (FEV1) of 80 % or less of the normal value, or a known high tendency for the airways to narrow (bronchial hyperreactivity).
  • Being allergic to any inactive ingredient (excipients) in the test solutions.
  • Receiving or having received allergy shots (allergen immunotherapy) for the test allergens or related allergens.
  • Having a serious overall disease affecting the liver, kidneys, heart, metabolism, an autoimmune disease, a weakened immune system, or an active infection or inflammation of the breathing passages.
  • Taking medicines called beta‑blockers.
  • Having taken or currently taking an anti‑IgE antibody medication (such as Omalizumab) or a cancer‑related checkpoint inhibitor.
  • Having a medical history that puts you at high risk for a severe allergic reaction called anaphylaxis.
  • Being pregnant or breastfeeding.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
HNO-Praxis Dr. med. Udo Schäfer Dresden Germany
Hhdhlgfd Gjafmtn Dl Vsruijjlecbhs Villarrobledo Spain
Hvnvsoso Ugogsuuubvwcm Dy Lq Ptdpg Villarreal Spain
Cnslqri Cnmvfyak Barcelona Spain
Hdvucqpr Upblwmegyyiyy Dw Bfqnjmy Badajoz Spain
Hsd Zutrtyp af Kmpzml Berlin Germany
Hnsubpshek Afup Pznc Goettingen Germany
Pfsbew fmi Hnu udo Aoidubffhycl Drm Ydsl Yusdq Dresden Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not yet recruiting
01.09.2026
Spain Spain
Not yet recruiting
01.09.2026

Trial locations

SPT-RX-PAR is a skin‑prick test solution that contains pollen from the plant Parietaria judaica. In the trial, a tiny amount of this solution is placed on the skin and a small prick is made. If a person is allergic to this pollen, a skin reaction (like a small bump) will appear, helping doctors identify an IgE‑mediated allergy to Parietaria pollen.

SPT-RX-PHL is a skin‑prick test solution that contains pollen from Timothy grass (Phleum pratense). During the test, a small drop is applied to the skin and pricked. A positive skin reaction shows that the person has an IgE‑mediated allergy to Timothy grass pollen.

SPT-RX-BET is a skin‑prick test solution that contains pollen from the silver birch tree (Betula pendula). The solution is used in the same way as other skin‑prick tests: a drop is placed on the skin and lightly pricked. If the person is allergic to birch pollen, a skin bump will develop, indicating an IgE‑mediated birch allergy.

SPT-RX-DPT is a skin‑prick test solution that contains extract from the dust mite Dermatophagoides pteronyssinus. A small amount is applied to the skin and pricked. A reaction at the test site shows that the person has an IgE‑mediated allergy to this common house dust mite.

SPT-RX-OLE is a skin‑prick test solution that contains pollen from the olive tree (Olea europaea). The test involves placing a drop on the skin and making a tiny prick. If the person is allergic to olive pollen, a skin reaction will appear, indicating an IgE‑mediated olive allergy.

Allergic rhinitis – A condition in which the lining of the nose becomes inflamed after exposure to allergens such as pollen or dust mites. It causes sneezing, a runny or blocked nose, and itching. The symptoms may appear seasonally when specific plants release pollen, or they can occur year‑round with indoor allergens. Continuous exposure can lead to persistent nasal irritation and increased symptom frequency.

Allergic rhinoconjunctivitis – This disorder combines nasal inflammation with inflammation of the eye surface due to allergic triggers. Patients experience typical nasal symptoms together with itchy, watery, and red eyes. It can be triggered by the same seasonal or perennial allergens that cause allergic rhinitis. Ongoing exposure often makes the eye and nose symptoms flare together and become more chronic.

Mild-to-moderate asthma – A chronic disease where the airways become inflamed and narrow, leading to wheezing, coughing, and shortness of breath. Symptoms are usually triggered by allergens, cold air, or exercise. In the mild‑to‑moderate range, episodes may occur intermittently and are often linked to exposure levels. Repeated triggers can increase the frequency of breathing difficulties over time.

Trial ID:
2025-524676-32-00
Protocol code:
PT-3A2H
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies

    Recruiting

    3 1
    Portugal Spain
  • Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma.

    Recruiting

    3 1
    Investigated Diseases:
    Portugal Spain